Nano-Pulse Stimulation (NPS) in Cancer Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 626
Special Issue Editor
Interests: cell signal transduction; cancer mechanisms; cancer therapies and resistances to therapy; programmed cell death; mitochondrial functions; bioenergetics and metabolism; regulated and immunogenic cell death; pulsed electric field effects on cells, tumors and immunity
Special Issue Information
Over the last two decades, pulsed-power delivery of nanosecond-duration pulses with high-intensity and low, non-thermal energy to tumors, designated Nanopulse Stimulation (NPS), has evolved into successful treatment strategies for many different types of cancers in pre-clinical models. A recent PubMed search with “nanosecond” and “electric fields” returned 551 articles. Including the term “cancer,” the search identified a subgroup of 112 papers, with an average of 10 papers per year over the last decade. When adding “immunity” to these terms, 13 manuscripts, or over 11% of the cancer-related NPS manuscripts, were retrieved. While this field continues to grow, there are significant gaps in our wisdom regarding the cancer mechanisms against which NPS acts, the efficacy of NPS alone and in combination with other chemotherapeutic and immunotherapeutic agents, the modes of NPS-induced regulated cell death, as well as aspects of immune cell responses to NPS and how these responses influence cancer progression.
This Special Issue of Cancers aims to draw the attention of wider audiences to NPS technology, expand our perceptions of NPS technology, find niches for NPS in therapeutic strategies (alone and in combination with other agents), and define how NPS shapes immunosurveillance in the aftermath of tumor treatments. This Special Issue is also open to studies on other aspects on NPS that can broaden our perception of the use ultra-short electric pulses in cancer therapy.
Prof. Dr. Stephen J. Beebe
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- regulated cell death (RCD)
- apoptosis
- immunogenicity
- immunity
- membranes
- mitochondria
- intracellular
